KEYNOTE-598 confirms current standard of care in metastatic 1L NSCLC patients with PD-L1 TPS ≥50%

Results from the head-to-head phase 3 KEYNOTE-598 trial with pembrolizumab in combination with ipilimumab versus pembrolizumab monotherapy in metastatic NSCLC patients with PD-L1 TPS ≥50% and with no targetable EGFR or ALK aberrations were presented at WCLC 2020 Presidential Symposium.